COMBINED LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG AND EXOGENOUS GONADOTROPINS FOR THE TREATMENT OF INFERTILITY ASSOCIATED WITH POLYCYSTIC OVARIES

被引：81

作者：

HOMBURG, R

ESHEL, A

KILBORN, J

ADAMS, J

JACOBS, HS

机构：

[1] Cobbold Laboratories, Middlesex Hospital

来源：

HUMAN REPRODUCTION | 1990年 / 5卷 / 01期

关键词：

Gonadotrophins; Infertility; LHRH analogue; PCO;

D O I：

10.1093/oxfordjournals.humrep.a137035

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

This study was designed to compare the results of treatment with, firstly, exogenous gonadotrophins, with (57 cycles) and without (65 cycles) pretreatment with a superactive analogue of luteinizing hormone releasing hormone (LHRH) and, secondly, pure follicle stimulating hormone (FSH) (50 cycles) with those of human menopausal gonadotrophin (HMG) (72 cycles) in 46 women with clomiphene-citrate-resistant anovulation associated with polycystic ovaries. Patients randomly allocated to the analogue group received buserelin (Suprefact, Hoechst, UK, Ltd, Hounslow, Middlesex), 800 /μg/day by nasal insufflation and when hypogonadism was achieved, patients were again randomly allocated for ovarian stimulation with either FSH or HMG. Controls received FSH or HMG alone. Patients pretreated with the analogue had similar pregnancy and ovulation rates, needed larger doses and more days of gonadotrophin therapy and had more ovarian overstimulation than those receiving no pretreatment. The role of superactive LHRH analogues for induction of a single ovulation for in-vivo fertilization is thus uncertain. Pure FSH had no advantages over HMG, the LH content of HMG having no deleterious effect on the ovary. © 1990 Oxford University Press.

引用

页码：32 / 35

页数：4

共 15 条

[1] Adarns J., Franks S., Poison D.W., Multifollicular ovaries
[2] clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone, Lancet, 11, pp. 1375-1378, (1985)
[3] Adams J., Tan S.L., Wheeler M.J., Morris D.V., Jacobs H.S., Franks S., Uterine growth in the follicular phase of spontaneous ovulatory cycles and during luteinizing hormone-releasing hormone induced cycles in women with normal or polycystic ovaries, Fertil. Steril, 49, pp. 52-56, (1988)
[4] Dor J., Itzkovic D.J., Mashiach S., Lunenfeld B., Serr D.M., Cumulative conception rates following gonadotropin therapy, Am. J. Obstet. Gynecol, 13, pp. 102-107, (1980)
[5] Eshel A., Abdulwahid N.A., Armar N.A., Adams J.M., Jacobs H.S., Pulsatile luteinizing hormone-releasing hormone therapy in women with polycystic ovary syndrome, Fertil. Steril, 49, pp. 956-960, (1988)
[6] Fleming R., Hatton M.J., Hamilton M.P.R., McCune G.S., Black W.P., Macnaughton M.C., Coutts J.R.T., Successful treatment of infertile women with oligomenorrhoea using a com bination of an LHRH agonist and exogenous gonadotrophins, Br. J. Obstet. Gynaecol, 92, pp. 369-373, (1985)
[7] Franks S., Poison D.W., Mason H.D., Pulsatile low-dose gonadotrophin therapy in women with polycystic ovaries, pp. 243-247, (1987)
[8] Homburg R., Armar N.A., Eshel A., Adams J., Jacobs H.S., The influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in patients with polycystic ovary syndrome, Br. Med. J, 29, pp. 1024-1026, (1988)
[9] Howies C.M., Macnamee M.C., Edwards R.G., Goswamy R., Steptoe P.C., Effect of high tonic levels of luteinising hormone on outcome of in vitro fertilisation, Lancet, 2, pp. 521-528, (1986)
[10] Jacobs H.S., Porter R.N., Eshel A., Craft I., Profertility uses of LHRH analogues, LHRH and Its Analogues: Contraceptive and Therapeutic Applications, Part, 2, pp. 303-322, (1987)

← 1 2 →